Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials.

Once-daily povorcitinib 30 mg improved facial repigmentation in adults with moderate-to-severe nonsegmental vitiligo, achieving F-VASI75 at week 52 in 18.9% vs 6.8% (STOP-V1) and 18.9% vs 3.1% (STOP-V2).

• Why it matters: There is an unmet need for systemic repigmentation options in nonsegmental vitiligo patients who are candidates for systemic therapy.
• What they did: Two parallel phase 3 randomized, double-blind, placebo-controlled STOP-V trials enrolled 467 (STOP-V1) and 449 (STOP-V2) adults, testing once-daily oral povorcitinib 30 mg with F-VASI75 at week 52 as the primary endpoint.
• The result: F-VASI75 at week 52 was statistically significant in both trials (STOP-V1 odds ratio 3.1, P=0.0003; STOP-V2 odds ratio 7.5, P<0.0001), with similar any TEAE rates (68.7%/66.7% vs 63.7%/62.7%) and generally single serious TEAEs.

AI summary of the abstract · may contain errors · not medical advice · read the paper.